文献速递腹部CT

基于术前胰腺对比增强CT表现对根治性切除术后胰腺导管腺癌患者进行预后分层

Prognostic stratification in patients with pancreatic ductal adenocarcinoma after curative resection based on preoperative pancreatic contrast-enhanced CT findings.
PubMed 文献 · Eur J Radiol · 2022-04-12

回顾性分析2014年1月至2020年6月126例根治性切除的胰腺导管腺癌患者,按90例开发队列和36例验证队列分组,基于术前胰腺对比增强CT表现构建列线图预测无复发生存期和总生存期;肿瘤>4cm、邻近器官侵犯、可疑淋巴结和边缘强化与更差的无复发生存期和总生存期独立相关,列线图区分能力良好且优于TNM分期,可将患者分为低危和高危组。

要点

  • 肿瘤大小>4cm、邻近器官侵犯、可疑淋巴结和边缘强化是胰腺导管腺癌根治术后无复发生存期和总生存期的独立不良预后因素。
  • 基于术前胰腺对比增强CT的列线图在验证队列中区分能力良好,预测结局优于TNM分期系统。
  • 列线图可将患者分为低危和高危组,低危组无复发生存期和总生存期率显著高于高危组。

核心结论

  • 基于术前胰腺对比增强CT表现的列线图可预测胰腺导管腺癌根治性切除术后无复发生存期和总生存期,并有助于进一步预后分层。

研究设计与样本

  • 回顾性研究,纳入2014年1月至2020年6月126例根治性切除的胰腺导管腺癌患者,分为开发队列90例和验证队列36例,基于Cox比例风险回归模型构建列线图,在验证队列中验证,评估校准、区分度和临床效用。

关键影像表现/征象

  • 肿瘤大小>4cm、邻近器官侵犯、可疑淋巴结和边缘强化在单因素和多因素分析中均与更差的无复发生存期和总生存期独立相关(所有P值<0.05)。

临床应用与阅片要点

  • 术前胰腺对比增强CT评估肿瘤大小>4cm、邻近器官侵犯、可疑淋巴结和边缘强化有助于识别根治性切除术后预后不良的胰腺导管腺癌患者。
  • 基于上述CT表现的列线图可用于预后分层,验证队列中其预测结局优于TNM分期系统。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To establish a prognostic stratification model for predicting prognosis in patients with pancreatic ductal adenocarcinoma (PDAC) after curative resection based on preoperative contrast-enhanced computed tomography (CECT) findings.

METHOD: From January 2014 to June 2020, 126 patients with radically resected PDAC were reviewed and divided into a development cohort (n = 90) and a validation cohort (n = 36). In the development cohort, clinicopathological parameters and preoperative CECT findings associated with recurrence-free survival (RFS) and overall survival (OS) were identified by using univariate and multivariate analyses. Nomograms were constructed based on Cox proportional hazards regression models. New prognostic nomograms were certificated in the validation cohort. Model performance was evaluated based on calibration, discrimination, and clinical utility.

RESULTS: Tumor size >4 cm, adjacent organs invasion, suspicious lymph nodes, and rim enhancement were independently associated with worse RFS and OS (all P values were < 0.05). In the validation cohort, the nomograms based on pancreatic CECT showed good discrimination capability and outperformed the TNM staging system in outcomes prediction. Patients were stratified into low- and high-risk groups based on nomograms, and RFS and OS rates in the low-risk group were significantly higher than those in the high-risk group (P < 0.001 and <0.01, respectively).

CONCLUSIONS: Nomograms based on preoperative pancreatic CECT findings can predict RFS and OS for PDAC patients after curative resection and facilitate further prognostic stratification.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Li, Wang, Cai, et al. Prognostic stratification in patients with pancreatic ductal adenocarcinoma after curative resection based on preoperative pancreatic contrast-enhanced CT findings. Eur J Radiol. 2022. PMID: 35447500. doi:10.1016/j.ejrad.2022.110313

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。